Metformin

Metformin is a cheap, decades-old diabetes drug that became the internet's favorite anti-aging pill. For people with type-2 diabetes, the enthusiasm makes sense. For healthy people hoping to slow aging, the evidence doesn't hold up, and one of the best things you can do for longevity may work less well if you take it.

What metformin does

The drug inhibits mitochondrial complex I and activates AMPK, the cell's low-energy sensor. That nudges down mTOR signaling and encourages autophagy, mimicking some of what caloric restriction does biochemically. Nir Barzilai has built a serious scientific case around this "CR-mimetic" rationale [1], and the biology is real. The unresolved question is whether that signal translates into longer, healthier lives in people who don't have diabetes.

The diabetes case is solid

In overweight people with type-2 diabetes, metformin cuts all-cause mortality by roughly 36% compared with conventional treatment [2]. It reduces complications, it's inexpensive, and it has decades of use behind it with a well-understood safety profile. This is a good drug for the condition it treats.

The longevity hype rests on a flawed study

The excitement about metformin for healthy people traces largely to a 2014 paper by Bannister and colleagues suggesting that diabetics taking metformin outlived matched non-diabetics. That finding looked extraordinary because it implied the drug was doing something beyond glucose control. A 2023 reanalysis identified the result as a monotherapy-exclusion artifact; correcting for it, the effect disappears [3], [4]. The confounded observation that launched a thousand supplement stacks does not survive scrutiny.

Animal data offers no rescue. In the Interventions Testing Program, metformin alone did not extend lifespan in mice [5]. Rapamycin did. Metformin's longevity case currently has no solid animal proof and no completed human trial.

It blunts exercise, and exercise is the intervention with actual evidence

A controlled study by Konopka and colleagues found that metformin attenuated gains in VO₂max, insulin sensitivity, and mitochondrial function from exercise training in older adults [6]. This is the crux of the practical concern: if your goal is longevity, aerobic fitness and muscle mass are among the most powerful levers available. A drug that dulls both, in people who don't need it for glucose control, trades a speculative benefit for a measurable cost.

Peter Attia stopped taking metformin around 2018 after measuring his own resting lactate at 1.6 mmol/L while fasting [7]. He attributes this to complex-I inhibition diverting glucose toward lactate rather than through oxidative phosphorylation. His concern is specific: improved background lactate compresses the zone-2 exercise window, making it harder to train at the intensity that drives mitochondrial adaptation, and blunts muscle hypertrophy [7]. He subsequently switched to an SGLT2 inhibitor, which targets glucose and insulin metabolism without the mitochondrial inhibition [7]. The mechanistic reasoning is coherent, but the lactate observation came from his own self-tracking, not a controlled study. It is his informed opinion, not a clinical finding [7].

What would change the picture

The TAME (Targeting Aging with Metformin) trial was set up precisely to test whether metformin delays age-related disease in non-diabetic older adults [8]. It has not yet been completed. Until those results exist, any claim that metformin extends healthy human lifespan is ahead of the evidence.

Where the evidence is contested

The mechanistic rationale for metformin as a longevity drug is not in dispute. AMPK activation and mild mTOR suppression are plausible aging-relevant pathways, and Barzilai's work takes them seriously [1]. What remains contested is whether the magnitude of those signals in humans is large enough to matter for lifespan or healthspan, and whether the exercise-blunting effect cancels any benefit in active people.

The exercise-interference data from Konopka et al. [6] studied older adults over a defined training period; critics note the effect size and its durability across different populations aren't fully established. Attia's lactate concern [7] is mechanistically coherent but rests on personal observation, not a randomized comparison. Proponents of metformin for longevity argue the drug's risks are low and the potential upside of even modest mTOR suppression justifies use while waiting for TAME [8]. Skeptics counter that recommending an exercise-impairing drug to healthy, active people on the basis of unconfirmed animal and epidemiological signals gets the risk-benefit math backwards. Both positions are reasonable given current data; neither is settled.

References

1. Attia #204 — Nir Barzilai: centenarians, metformin, longevity
2. UKPDS 34, 1998, Lancet — metformin in overweight T2D · PubMed 9742977
3. Bannister et al. 2014, Diabetes Obes Metab — metformin survival (refuted) · PubMed 25041462
4. Physionic (Verhoeven) — metformin, the anti-aging drug… or is it?
5. ITP (Strong/Miller) 2016, Aging Cell — metformin alone null (mouse)
6. Konopka et al. 2019, Aging Cell — metformin blunts exercise · PubMed 30548390
7. Attia ep270 — Metformin journal club (Attia + Huberman)
8. Barzilai et al. 2016, Cell Metab — "Metformin as a Tool to Target Aging" (TAME) · PubMed 27304507